Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E M Fielden

Showing results (71-80 of 86) with videos related to

Pageof 9
Sort By:
FEBS Letters|June 1, 1973
The superoxide dismutase activity of human erythrocupreinJ V Bannister, W H Bannister, R C Bray, et al.
The Biochemical Journal|April 1, 1974
Mechanism of action of superoxide dismutase from pulse radiolysis and electron paramagnetic resonance. Evidence that only half the active sites function in catalysisE M Fielden, P B Roberts, R C Bray, et al.
International Journal of Radiation Oncology, Biology, Physics|January 1, 1992
Assessment of a range of novel nitro-aromatic radiosensitizers and bioreductive drugsE M Fielden, G E Adams, S Cole, et al.
International Journal of Radiation Oncology, Biology, Physics|May 15, 1994
Radiolytic and photochemical reduction of the hypoxic cytotoxin 1,2-dihydro-8-(4-methylpiperazinyl)-4-phenylimidazo [1,2-a] pyrido [3,2-e] pyrazine 5-oxide (RB90740) and a potential mechanism for hypoxia-selective toxicityM A Naylor, B M Sutton, J Nolan, et al.
International Journal of Radiation Oncology, Biology, Physics|July 1, 1986
Analogues of RSU-1069: radiosensitization and toxicity in vitro and in vivoI Ahmed, T C Jenkins, J M Walling, et al.
International Journal of Radiation Oncology, Biology, Physics|May 15, 1994
Pharmacokinetics, metabolism and distribution of 1,2-dihydro-8-(4-methylpiperazinyl)-4-phenylimidazo [1,2-A] pyrido [3,2-E] pyrazine-5-oxide in C3H miceB M Sutton, N J Reeves, M A Naylor, et al.
International Journal of Radiation Oncology, Biology, Physics|July 1, 1986
Studies on the mechanisms of the radiosensitizing and cytotoxic properties of RSU-1069 and its analoguesJ M Walling, I J Stratford, G E Adams, et al.
International Journal of Radiation Oncology, Biology, Physics|January 1, 1992
Dual function nitroimidazoles less toxic than RSU 1069: selection of candidate drugs for clinical trial (RB 6145 and/or PD 130908S Cole, I J Stratford, E M Fielden, et al.
Journal of Medicinal Chemistry|September 18, 1992
2-Nitroimidazole dual-function bioreductive drugs: studies on the effects of regioisomerism and side-chain structural modifications on differential cytotoxicity and radiosensitization by aziridinyl and oxiranyl derivativesM A Naylor, M D Threadgill, P Webb, et al.
Drug Design and Discovery|January 1, 1993
Synthesis of the enantiomers of the bioreductively-activated cytotoxin RSU-1069 and its prodrug RB6145 and lack of stereoselectivity in their cytotoxicity and radiosensitization in vitroM A Naylor, M D Threadgill, H D Showalter, et al.
Pageof 9

Showing results (71-80 of 86) with videos related to

Sort By:
Pageof 9
FEBS Letters|June 1, 1973
The superoxide dismutase activity of human erythrocupreinJ V Bannister, W H Bannister, R C Bray, et al.
The Biochemical Journal|April 1, 1974
Mechanism of action of superoxide dismutase from pulse radiolysis and electron paramagnetic resonance. Evidence that only half the active sites function in catalysisE M Fielden, P B Roberts, R C Bray, et al.
International Journal of Radiation Oncology, Biology, Physics|January 1, 1992
Assessment of a range of novel nitro-aromatic radiosensitizers and bioreductive drugsE M Fielden, G E Adams, S Cole, et al.
International Journal of Radiation Oncology, Biology, Physics|May 15, 1994
Radiolytic and photochemical reduction of the hypoxic cytotoxin 1,2-dihydro-8-(4-methylpiperazinyl)-4-phenylimidazo [1,2-a] pyrido [3,2-e] pyrazine 5-oxide (RB90740) and a potential mechanism for hypoxia-selective toxicityM A Naylor, B M Sutton, J Nolan, et al.
International Journal of Radiation Oncology, Biology, Physics|July 1, 1986
Analogues of RSU-1069: radiosensitization and toxicity in vitro and in vivoI Ahmed, T C Jenkins, J M Walling, et al.
International Journal of Radiation Oncology, Biology, Physics|May 15, 1994
Pharmacokinetics, metabolism and distribution of 1,2-dihydro-8-(4-methylpiperazinyl)-4-phenylimidazo [1,2-A] pyrido [3,2-E] pyrazine-5-oxide in C3H miceB M Sutton, N J Reeves, M A Naylor, et al.
International Journal of Radiation Oncology, Biology, Physics|July 1, 1986
Studies on the mechanisms of the radiosensitizing and cytotoxic properties of RSU-1069 and its analoguesJ M Walling, I J Stratford, G E Adams, et al.
International Journal of Radiation Oncology, Biology, Physics|January 1, 1992
Dual function nitroimidazoles less toxic than RSU 1069: selection of candidate drugs for clinical trial (RB 6145 and/or PD 130908S Cole, I J Stratford, E M Fielden, et al.
Journal of Medicinal Chemistry|September 18, 1992
2-Nitroimidazole dual-function bioreductive drugs: studies on the effects of regioisomerism and side-chain structural modifications on differential cytotoxicity and radiosensitization by aziridinyl and oxiranyl derivativesM A Naylor, M D Threadgill, P Webb, et al.
Drug Design and Discovery|January 1, 1993
Synthesis of the enantiomers of the bioreductively-activated cytotoxin RSU-1069 and its prodrug RB6145 and lack of stereoselectivity in their cytotoxicity and radiosensitization in vitroM A Naylor, M D Threadgill, H D Showalter, et al.
Pageof 9